VKH
ELDN icon

Virtu KCG Holdings’s Eledon Pharmaceuticals ELDN Stock Holding History

Virtu KCG Holdings’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-247
Closed -$33K – 3013
2017
Q1 		$33K Buy
247
+148
+149% +$21.7K ﹤0.01% 2911
2016
Q4 		$16K Buy
+99
New +$19K ﹤0.01% 3255
2015
Q4 		– Sell
-71
Closed -$119K – 3584
2015
Q3 		$119K Buy
+71
New +$146K ﹤0.01% 2778

Other funds holding ELDN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Virtu KCG Holdings's ELDN Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Eledon Pharmaceuticals (ELDN) in Q2 2017, closing a stake of 247 shares — an estimated $33K sold.

Virtu KCG Holdings first reported a position in ELDN in Q3 2015 and held it in 3 quarters. The position peaked at $119K in Q3 2015. 19 funds tracked by Wall St. Rank hold ELDN as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Eledon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 247 Eledon Pharmaceuticals shares in Q2 2017, an estimated $33K.
  • Virtu KCG Holdings first reported a position in Eledon Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Virtu KCG Holdings's Eledon Pharmaceuticals position peaked at $119K in Q3 2015.
  • 19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.